ClinicalTrials.gg
RecruitingNCT06087276Updated Oct 6, 2026

Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)

A Phase 3 interventional study of 60 mg ulixacaltamide and Placebo in Essential Tremor, sponsored by Praxis Precision Medicines. Recruiting at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Praxis Precision Medicines · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.
Updated Oct 6, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 146 studies in Essential Tremor with a site in United States — 40 open to participants now, 46 under way, 1 of them phase 3. Essential Tremor · United States.

Planned enrollment
Largest of 104
1,000 · median 30
Started
2023
with 3 others
Phase 3
3 of 146
1 open now
Primary completion
2025-10
later than 2 of 44 live
Registered
124th of 146
by date
Lead sponsor
4 of 146
Praxis Precision Medicines

Among the 146 studies in Essential Tremor with a site in United States, this one has the largest planned enrollment of the 104 interventional ones that give a count, is one of 4 that started in 2023, is one of 3 in phase 3, reaches primary completion later than 2 of the 44 other live ones, and was the 124th registered.

Essential Tremor

272 studies on the registry are indexed under Essential Tremor; 75 are open to participants now.

Browse Essential Tremor studies →

Open to participants now

40 of the 146 studies in Essential Tremor with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 61 Essential Tremor studies recruiting now, 32 (52%) set no upper age limit and 5 (8%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 146 studies in Essential Tremor with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical study is to compare ulixacaltamide and placebo treatment in essential tremor. The main question it aims to answer is:

  • Is ulixacaltamide a safe and efficacious treatment for patients with essential tremor?

Participants will be asked to participate in one of two clinical studies where they will be treated with either ulixacaltamide or placebo for a period of up to 12 weeks. After the controlled study completion, they will be eligible to participate in a long-term, open-label safety study (LTSS) and be treated with ulixacaltamide. Participants are eligible to enroll directly into the LTSS if they previously participated in an essential tremor trial, received sponsor invitation after being deemed ineligible for the controlled study, or following enrollment closure of the controlled study.

Read the detailed description

PRAX-944-321 is a decentralized, Phase 3, multi-study, clinical trial evaluating the safety and efficacy of ulixacaltamide in essential tremor (ET). The study includes 3 separate and simultaneous phase 3 pivotal studies where all participants undergo one screening process. The first study is a parallel design (PD) enrolling approximately 400 patients, the second is a randomized withdrawal (RW) enrolling approximately 200 patients and the last is a long-term safety study (LTSS) comprising up to 1000 patients.

A total of 4 key efficacy hypotheses are being tested prospectively in the study. The analysis will be conducted simultaneously, with unblinding only occurring once. Hypotheses - 1) how do patients compare between ulixacaltamide and placebo after 56 days of intervention in the PD study, 2) for patients exposed to ulixacaltamide in the RW study who improved by at least 3 points in the mADL11 scale, which proportion maintains response after randomization staying on ulixacaltamide compared to placebo after re-randomization at day 56, 3) how does the pooled group of patients receiving ulixacaltamide in both studies (PD and RW) compare to placebo patients from the parallel design study after 56 days of intervention, 4) how do patients receiving ulixacaltamide in the RW study compare to placebo patients from the PD study after 56 days of intervention.

03

Conditions studied

  • Essential Tremor

Keywords

  • Movement Disorder
  • Benign Essential Tremor
  • Familial Tremor
  • Hereditary Essential Tremor
  • Movement Disorder Agents
  • Calcium Channels, T-type
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has a (BMI) at Screening of ≥18 kg/m2.
  2. Has a clinical diagnosis of ET confirmed during screening and characterized by postural and action tremor.
  3. If currently receiving medication prescribed for ET, must be on ≤1 medications, on stable dose(s) for at least 1 month prior to Screening, and willing to maintain stable dose(s) throughout the study. As needed (PRN) use of prescribed ET medicines is not allowed with the exception of propranolol PRN. Participants prescribed propranolol PRN are eligible but must discontinue the PRN dose after the first day of screening. Primidone use is not allowed within 2 weeks prior to screening and throughout duration of study.
  4. Women of must undertake pregnancy tests, with a documented negative serum pregnancy test at Screening, negative urine pregnancy tests at Baseline (Day 1) prior to administration of study drug, throughout the intervention periods (as outlined in the SoA) and at the SFU or ED Visit, as appropriate.
  5. Is willing and able to use as defined in the protocol and ICF.
  6. Has been assessed as an appropriate and suitable candidate by investigator and has a neurological exam and medical record(s) consistent with ET diagnosis, as confirmed by the ERC central reviewer.
  7. Confirm key inclusion criteria at Baseline

Exclusion criteria

Exclusion Criteria for Study 1 PD and Study 2 RW:

  1. Neuropathy, muscle weakness, arthropathy or other musculoskeletal diagnosis of the upper extremity that impairs dexterity or function.
  2. Has a known to any component of the formulation of ulixacaltamide.
  3. Is unwilling or unable to refrain from episodic use of medication(s)/substance(s) that might interfere with the evaluation of tremor during the study.
  4. Is sporadically using a benzodiazepine, sleep medication or anxiolytic (as further defined in the protocol), that in the judgement of the investigator or sponsor would confound the assessment of tremor.
  5. Has trauma to the nervous system within 3 months preceding the onset of tremor.
  6. Has a history of unilateral tremor or clinical evidence of another medical, neurological, or psychiatric condition that may explain or cause tremor, including but not limited to Parkinson's disease, Huntington's disease, Alzheimer's disease, stroke with neurologic sequelae, intention tremor (IT) caused by etiology other than ET, cerebellar disease (including spinocerebellar ataxias), primary dystonia, Fragile X Tremor/Ataxia syndrome or family history of Fragile X syndrome, traumatic brain injury, psychogenic tremor, alcohol or benzodiazepine abuse or withdrawal, multiple sclerosis, polyneuropathy (diabetic neuropathy allowed if disease does not affect gait or balance and does not involve upper extremity), and endocrine states such as uncontrolled or inadequately treated hypothyroidism, food, or supplement induced movement disorders (e.g., tremor related to beta agonists or caffeine), or other medical, neurological, or psychiatric conditions that may explain or cause tremor.
  7. Has had prior magnetic resonance-guided focused ultrasound or surgical intervention for ET such as a deep brain stimulator (DBS) or lesion therapy such as thalamotomy.
  8. Has had botulinum toxin injection for ET in the 6 months prior to Screening or throughout the study.
  9. Is using the Cala trio health device for ET in 14 days prior to Screening or throughout the study.
  10. Is unwilling or unable to refrain from drinking alcohol 24 hours before and during clinical study assessments, or regular use of alcohol that would preclude abstinence from alcohol for this time period around visits.
  11. Has a history of substance use disorder consistent with Fifth Edition Text Revision (DSM-5-TR) criteria. Participants with a previous diagnosis of substance use disorder who have been in remission for at least 2 years can participate in the study.
  12. Is currently pregnant or breastfeeding or is planning to become pregnant during the clinical trial or within 31 days of the last study drug dose.
  13. Is currently taking a prescription or non-prescription product(s) and food known to be moderate or strong inhibitors or strong inducers (moderate inducers are not prohibited) of cytochrome P450 (), which cannot be discontinued at least 5 half-lives or 14 days prior (whichever is the longer period of time) to Baseline and withheld throughout the clinical study.
  14. Has received any experimental or drug, device, or other therapy within 30 days or 5 half-lives (whichever is longer) prior to Screening.
  15. Has any of the following abnormal test results at Screening: a serum total value >1.5× (ULN); a serum (ALT) or aspartate aminotransferase (AST) value >2×ULN. As an exception, participants that present with elevated bilirubin in the absence of elevations in ALT or AST that fits the pattern of Gilbert's syndrome may be enrolled after discussion with the medical monitor and/or sponsor designee if their conjugated bilirubin is below the ULN.
  16. History of (HIV) infection or positive screening result for: HIV 1 or 2 antibodies, surface antigen (HBsAg) or hepatitis B core antibody (HBcAb), or virus antibody (HCVAb).
  17. History of long syndrome and/or a Fridericia formula corrected QT interval (QTcF) interval >450 msec (males) or >460 msec (females) per (ECG) done at Screening.
  18. Any major psychiatric disorder, including but not limited to depression and anxiety, that is uncontrolled (for the past 90 days) or, in the investigator's judgment, can interfere with any of the study procedures.
  19. Has a lifetime history of any suicide attempt, or suicidal ideation with intent within the past 2 years prior to Screening.
  20. Participants who have a history of , myeloproliferative or lymphoproliferative disorders within the past 5 years prior to screen are excluded.

    Exceptions:

    • Participants with completely excised non-melanoma skin cancer (such as basal cell carcinoma or squamous cell carcinoma) or cervical carcinoma in situ are permitted at any time.
    • Participants with a history of other malignancies deemed cured by adequate treatment are also permitted at any time.
  21. Has any other significant disease or disorder including but not limited to uncontrolled seizure or epilepsy, diabetes, cardiovascular disease, renal disease, laboratory abnormalities, or environmental factor that, in the opinion of the investigator or sponsor designee, may either put the participant at risk due to participation in the clinical trial, may influence or confound the result of the clinical trial, or may affect the participant's ability to participate in the clinical trial. Uncontrolled epilepsy or seizure is exclusionary and is defined as a seizure or epilepsy diagnosed by a medical clinician and a documented seizure or change in seizure medication (medication or dose) in the last 2 years. An estimated (eGFR) of \<60 using the 2021 Chronic Kidney Disease-Epidemiology (CKD-EPI) formula mL/min/1.73m2 or urine albumin creatinine ratio (uACR) of ≥ 30 mg/g is exclusionary.
  22. Participant has a positive alcohol or drug screening (including cannabis and cannabis-derived products). The participant can be enrolled in the study, if they are willing to stop use of cannabis or cannabis-related products after the Screening Visit and have a negative cannabidiol (CBD) screen result at Baseline (Day 1). A positive amphetamine, benzodiazepine or opioid drug screening result could be allowed if it is determined that the result is a false positive (for example caused by another medication), or if the result is due to a documented prescribed medication (for example: benzodiazepine or opioid) that in the opinion of the investigator or sponsor designee, is prescribed for a medical condition that aligns with standard of care, is not associated with substance abuse and the investigator's assessment determines that the medical condition and medication dose is stable and expected to remain stable throughout the trial.
  23. History of or evidence of psychogenic tremor
  24. Prior participation in an ulixacaltamide clinical trial at any time or other clinical trial evaluating a potential drug for ET in the past 6 months (with the exception of participants with documentation that they received placebo treatment only), with the exception of participants that are currently enrolled in and complete the EOT visit in PRAX-944-222 extension period.

Inclusion Criteria for Direct Enrollment into Study 3 LTSS (Following Closure of Enrollment for Study 1 PD and Study 2 RW)

  1. Has a clinical diagnosis of ET confirmed during screening and characterized by postural and action tremor.
  2. Women of must undertake pregnancy tests, with a documented negative serum pregnancy test at Screening, negative urine pregnancy tests prior to administration of study drug, throughout the intervention periods (as outlined in the SoA) and at the SFU or ED Visit, as appropriate.
  3. Is willing and able to use .
  4. Has been assessed as an appropriate and suitable candidate by investigator and has a neurological exam and medical record(s) consistent with ET diagnosis, as confirmed by the ERC central reviewer.

Exclusion Criteria for Direct Enrollment into Study 3 LTSS (Following Closure of Enrollment for Study 1 PD and Study 2 RW)

  1. Has a known hypersensitivity to any component of the formulation of the ulixacaltamide.
  2. Has trauma to the nervous system within 3 months preceding the onset of tremor.
  3. Has a history of unilateral tremor or clinical evidence of another medical, neurological, or psychiatric condition that may explain or cause tremor.
  4. Has deep brain stimulator (DBS) that in the investigator's discretion is associated with significant stimulation side effects that could impact participant safety.
  5. Has a history of substance use disorder consistent with Diagnostic and Statistical Manual of Mental Disorders Fifth Edition Text Revision (DSM-5-TR) criteria. Participants with a previous diagnosis of substance use disorder who have been in remission for at least 2 years can participate in the trial.
  6. Is currently pregnant or breastfeeding or is planning to become pregnant during the clinical trial or within 31 days of the last study drug dose.
  7. Has received any experimental or investigational drug, device, or other therapy within 30 days or 5 half-lives (whichever is longer) prior to Screening.
  8. Has any of the following abnormal test results at Screening: a serum total bilirubin value >1.5×upper limit of normal (ULN); a serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value >2×ULN.
  9. History of or active human immunodeficiency virus (HIV) infection or positive screening result for: HIV 1 or 2 antibodies. Evidence of active hepatitis B or hepatitis C infection.
  10. History of or currently comorbid long QT syndrome and/or a Fridericia formula corrected QT interval (QTcF).
  11. Any major psychiatric disorder, including but not limited to depression and anxiety, that is uncontrolled (for the past 90 days).
  12. Has a lifetime history of any suicide attempt, or suicidal ideation with intent within the past 2 years prior to Screening.
  13. Participants who have a history of malignancy, myeloproliferative or lymphoproliferative disorders within the past 5 years prior to screen are excluded.
  14. Has any other significant disease or disorder including but not limited to uncontrolled seizure or epilepsy, diabetes, cardiovascular disease, renal disease, laboratory abnormalities, or environmental factor.
  15. Participant has a positive drug screening associated with drug abuse or misuse.
  16. History of or evidence of psychogenic tremor.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,000 participants (estimated)

Study arms

  • Experimental
    Parallel Design: ulixacaltamide arm

    Double-blind Part: Oral dosing, once daily in the morning with titration over 14 days to 60 mg ulixacaltamide: 7 days of 20 mg, 7 days of 40 mg, 70 days of 60 mg

    Drug: 60 mg ulixacaltamide

  • Placebo comparator
    Parallel Design: placebo arm

    Double-blind Part: Oral dosing, once daily in the morning: 84 days of placebo

    Drug: Placebo

  • Experimental
    Randomized Withdrawal

    Double-blind Part: Oral dosing, once daily in the morning with titration over 14 days to 60 mg ulixacaltamide: 7 days of 20 mg, 7 days of 40 mg, 42 days of 60 mg Randomized Withdrawal Part: Following double-blind part: 1:1 randomization to placebo or 60 mg ulixacaltamide for 28 days

    Drug: 60 mg ulixacaltamide · Drug: Placebo

  • Experimental
    Long-term Safety Study: Essential1 rollovers

    Open-label Part: Oral dosing, once daily in the morning up to 3 years 60 mg ulixacaltamide

    Drug: 60 mg ulixacaltamide

  • Experimental
    Long-term Safety Study: Parallel Design and Randomized Withdrawal rollovers

    Open-label Part for patients previously on placebo: Oral dosing, once daily in the morning with titration over 14 days to 60 mg ulixacaltamide: 7 days of 20 mg, 7 days of 40 mg, up to 3 years 60 mg ulixacaltamide Open-label Part for patients previously on 60 mg ulixacaltamide: Oral dosing, once daily in the morning up to 3 years 60 mg ulixacaltamide

    Drug: 60 mg ulixacaltamide

  • Experimental
    Long-term Safety Study: Direct Enrollment to LTSS Study

    Oral dosing, once daily in the morning with titration over 14 days to 60 mg ulixacaltamide: 7 days of 20 mg, 7 days of 40 mg, up to 3 years 60 mg ulixacaltamide

    Drug: 60 mg ulixacaltamide

Interventions

  • DrugZ944Studies of Z944Z944 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Once daily oral treatment with titration

  • DrugPlacebo

    Once daily oral treatment

06

What researchers measure

Primary outcomes

  1. Parallel Design: Change from Baseline (CFB) to Week 8 (Day 56) on mADL11 score

    Modified Activities of Daily Living 11 (mADL11) is a composite sum of items 1 to 11 of the TETRAS-ADL subscale. The impact to each function is rated on a 5-point Likert scale from 0 to 4. Before calculating the total score, a scoring adjustment is applied to each item score. The modified score is calculated as the sum of all 11 items (with scoring adjustments) and ranges from 0 to 33 where larger values represent increased direct tremor impact to activities of daily living.

    Time frame: 8 weeks (56 days)

  2. Randomized Withdrawal: The proportion of participants that maintain response, as defined by change in mADL11 score, following randomized withdrawal

    Modified Activities of Daily Living 11 (mADL11) is a composite sum of items 1 to 11 of the TETRAS-ADL subscale. The impact to each function is rated on a 5-point Likert scale from 0 to 4. Before calculating the total score, a scoring adjustment is applied to each item score. The modified score is calculated as the sum of all 11 items (with scoring adjustments) and ranges from 0 to 33 where larger values represent increased direct tremor impact to activities of daily living. Change in patient response will compare the proportion of patients in the ulixacaltamide and placebo arm who maintain response based on RW baseline established at Week 8 (Day 56) following randomized withdrawal.

    Time frame: 12 weeks (84 days)

  3. Long-term Safety Study: Number of participants with Adverse Events (AE) and their severity.

    The number of participants with Adverse Events (AE) will be reported by preferred term

    Time frame: Up to 3 years

Secondary outcomes

  1. Parallel Design: Rate of Disease improvement as Measured by mADL11

    Compare the rate of disease improvement through Day 84 of ulixacaltamide and placebo arms, as measured by the slope of mADL11 over time.

    Time frame: 12 weeks (84 days)

  2. Parallel Design: PGI-C Change at Week 8 (Day 56)

    PGI-C assesses the participant's change in condition since baseline. The participant is required to assess their condition relative to Baseline (Pre-dose on Day 1) on a 7-point scale from 1 (very much improved) to 7 (very much worse). In all cases, the assessment should be made independent of whether the participant believes the change is drug-related or not.

    Time frame: 8 weeks (56 Days)

  3. Parallel Design: CGI-S Change from Baseline to Week 8 (Day 56)

    CGI-S assesses the clinician's impression of the participant's current illness state. The clinician should use his/her total clinical experience with this patient population and rate the current severity of the participant's ET on a 7-point scale from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).

    Time frame: 8 weeks (56 Days)

  4. Randomized Withdrawal: Rate of Disease Improvement as Measured by Slope of mADL11 from Day 56 to Day 84

    Compare the rate of disease improvement from Day 56 to Day 84 of ulixacaltamide and placebo arms.

    Time frame: 4 weeks (28 days)

  5. Randomized Withdrawal: PGI-C at Day 84

    PGI-C assesses the participant's change in condition. The participant is required to assess their condition relative to Baseline on a 7-point scale from 1 (very much improved) to 7 (very much worse). In all cases, the assessment should be made independent of whether the participant believes the change is drug-related or not.

    Time frame: 4 weeks (28 days)

  6. Randomized Withdrawal: CGI-S Change from RW Baseline (Day 56) to Day 84

    CGI-S assesses the clinician's impression of the participant's current illness state. The clinician should use is/her total clinical experience with this patient population and rate the current severity of the participant's ET on a 7-point scale from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).

    Time frame: 4 weeks (28 days)

07

Study locations

1 of 1 sites recruiting
  • United BioSource LLC
    Morgantown, West Virginia 26508, United States
    Recruiting
    • Study Coordinator Center · Contact866-718-6944
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Nov 2023 to primary completion in Oct 2025, 23 months.

Completion moved once since we started tracking on Sep 25, 2026: Jul 2028 → Mar 2027, on Oct 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2023
First posted
Oct 17, 2023
StartActual
Nov 2, 2023
Primary completionActual
Oct 10, 2025
CompletionEst.
Mar 2027was Jul 2028
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Oct 6, 2026
Sites
United BioSource LLC is now Recruiting
Oct 6, 2026
Study completion
Jul 2028→Mar 2027
Oct 6, 2026
Contact
Study contact now listed: added c•••@praxismedicines.com · •••8460. See the current contact
Oct 6, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • United BioSource LLC · Morgantown, United StatesContact added •••6944
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Active, not recruiting→Recruiting
    United BioSource LLC is now Recruiting
    Study completion Jul 2028→Mar 2027
    Contact Study contact now listed: added c•••@praxismedicines.com · •••8460. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • United BioSource LLC · Morgantown, United StatesContact added •••6944
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06087276
Lead sponsor
Praxis Precision Medicines
Responsible party
Sponsor
First posted
Oct 17, 2023
Start date
Nov 2, 2023
Primary completion
Oct 10, 2025
Completion
Mar 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Head of Pharmacovigilance, Praxis Precision Medicines
Contact
clinicaltrials@praxismedicines.com
617-300-8460
Director, Clinical Development
study director · Praxis Precision Medicines

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Z944

Start the discussion